Thrombotic microangiopathy is a form of antibody-mediated rejection (ABMR): it is the main complication of ABO-incompatible (ABOi)
kidney transplantation (KT). Herein, we report on two cases of ABMR with biological and histological features of
thrombotic microangiopathy (TMA) that were treated by
eculizumab after ABOi KT. The first patient presented with features of TMA at postoperative day (POD) 13. Because of worsening biological parameters and no recovery of kidney function, despite seven sessions of immunoadsorption, a
salvage therapy of
eculizumab was started on POD 23. Kidney function slightly improved during the first 4 months after
transplantation.
Eculizumab was stopped at month 4. However, kidney function worsened progressively, leading to dialysis at month 13 after
transplantation. The second patient presented with features of TMA at POD 1. In addition to immunoadsorption
therapy,
eculizumab was started on POD 6. Kidney function improved.
Eculizumab was stopped on POD 64 and immunoadsorption sessions were stopped on POD 102. At the last follow-up (after 9 months), eGFR was at 43 mL/min/1.73 m2. Our case reports show the beneficial effect of
eculizumab to treat ABMR after ABOi KT. However, it should be given early after diagnosing TMA associated with ABMR.